Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

1.

Lycopene enhances docetaxel's effect in castration-resistant prostate cancer associated with insulin-like growth factor I receptor levels.

Tang Y, Parmakhtiar B, Simoneau AR, Xie J, Fruehauf J, Lilly M, Zi X.

Neoplasia. 2011 Feb;13(2):108-19.

PMID:
21403837
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy.

Litzenburger BC, Creighton CJ, Tsimelzon A, Chan BT, Hilsenbeck SG, Wang T, Carboni JM, Gottardis MM, Huang F, Chang JC, Lewis MT, Rimawi MF, Lee AV.

Clin Cancer Res. 2011 Apr 15;17(8):2314-27. doi: 10.1158/1078-0432.CCR-10-1903. Epub 2010 Dec 22.

PMID:
21177763
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer.

Dayyani F, Varkaris A, Araujo JC, Song JH, Chatterji T, Trudel GC, Logothetis CJ, Gallick GE.

Prostate. 2013 Jun;73(9):979-85. doi: 10.1002/pros.22645. Epub 2013 Jan 31.

PMID:
23371521
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Antisense oligonucleotide targeting of insulin-like growth factor-1 receptor (IGF-1R) in prostate cancer.

Furukawa J, Wraight CJ, Freier SM, Peralta E, Atley LM, Monia BP, Gleave ME, Cox ME.

Prostate. 2010 Feb 1;70(2):206-18. doi: 10.1002/pros.21054.

PMID:
19790231
[PubMed - indexed for MEDLINE]
5.

Co-administration of piperine and docetaxel results in improved anti-tumor efficacy via inhibition of CYP3A4 activity.

Makhov P, Golovine K, Canter D, Kutikov A, Simhan J, Corlew MM, Uzzo RG, Kolenko VM.

Prostate. 2012 May 1;72(6):661-7. doi: 10.1002/pros.21469. Epub 2011 Jul 27.

PMID:
21796656
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation.

Morikawa Y, Koike H, Sekine Y, Matsui H, Shibata Y, Ito K, Suzuki K.

Biochem Biophys Res Commun. 2012 Mar 16;419(3):584-9. doi: 10.1016/j.bbrc.2012.02.089. Epub 2012 Feb 24.

PMID:
22387542
[PubMed - indexed for MEDLINE]
7.

Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.

Henry JY, Lu L, Adams M, Meyer B, Bartlett JB, Dalgleish AG, Galustian C.

Prostate. 2012 Jun 1;72(8):856-67. doi: 10.1002/pros.21488. Epub 2011 Oct 3.

PMID:
21968939
[PubMed - indexed for MEDLINE]
8.

Effect of lycopene on insulin-like growth factor-I, IGF binding protein-3 and IGF type-I receptor in prostate cancer cells.

Kanagaraj P, Vijayababu MR, Ravisankar B, Anbalagan J, Aruldhas MM, Arunakaran J.

J Cancer Res Clin Oncol. 2007 Jun;133(6):351-9. Epub 2007 Jan 12.

PMID:
17219202
[PubMed - indexed for MEDLINE]
9.
10.

Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors.

Wu JD, Haugk K, Coleman I, Woodke L, Vessella R, Nelson P, Montgomery RB, Ludwig DL, Plymate SR.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6153-60.

PMID:
17062692
[PubMed - indexed for MEDLINE]
Free Article
11.

Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.

Wang Z, Chakravarty G, Kim S, Yazici YD, Younes MN, Jasser SA, Santillan AA, Bucana CD, El-Naggar AK, Myers JN.

Clin Cancer Res. 2006 Aug 1;12(15):4755-65.

PMID:
16899627
[PubMed - indexed for MEDLINE]
Free Article
12.

Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response.

Dong J, Demarest SJ, Sereno A, Tamraz S, Langley E, Doern A, Snipas T, Perron K, Joseph I, Glaser SM, Ho SN, Reff ME, Hariharan K.

Mol Cancer Ther. 2010 Sep;9(9):2593-604. doi: 10.1158/1535-7163.MCT-09-1018. Epub 2010 Aug 17.

PMID:
20716637
[PubMed - indexed for MEDLINE]
Free Article
13.

A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo.

Ji QS, Mulvihill MJ, Rosenfeld-Franklin M, Cooke A, Feng L, Mak G, O'Connor M, Yao Y, Pirritt C, Buck E, Eyzaguirre A, Arnold LD, Gibson NW, Pachter JA.

Mol Cancer Ther. 2007 Aug;6(8):2158-67. Epub 2007 Aug 1.

PMID:
17671083
[PubMed - indexed for MEDLINE]
Free Article
14.

Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.

Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, Parnes HL, Trepel JB, Lee MJ, Kim YS, Sun H, Madan RA, Latham L, Jones E, Chen CC, Figg WD, Dahut WL.

J Clin Oncol. 2010 Apr 20;28(12):2070-6. doi: 10.1200/JCO.2009.25.4524. Epub 2010 Mar 22.

PMID:
20308663
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo.

Ikezoe T, Hisatake Y, Takeuchi T, Ohtsuki Y, Yang Y, Said JW, Taguchi H, Koeffler HP.

Cancer Res. 2004 Oct 15;64(20):7426-31.

PMID:
15492266
[PubMed - indexed for MEDLINE]
Free Article
16.

Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel.

Uzoh CC, Holly JM, Biernacka KM, Persad RA, Bahl A, Gillatt D, Perks CM.

Br J Cancer. 2011 May 10;104(10):1587-93. doi: 10.1038/bjc.2011.127. Epub 2011 Apr 12.

PMID:
21487405
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy.

Sundaram S, Durairaj C, Kadam R, Kompella UB.

Mol Cancer Ther. 2009 Jun;8(6):1655-65. doi: 10.1158/1535-7163.MCT-08-0988. Epub 2009 Jun 9.

PMID:
19509261
[PubMed - indexed for MEDLINE]
Free Article
18.

Up-regulation of insulin-like growth factor binding protein-3 by apigenin leads to growth inhibition and apoptosis of 22Rv1 xenograft in athymic nude mice.

Shukla S, Mishra A, Fu P, MacLennan GT, Resnick MI, Gupta S.

FASEB J. 2005 Dec;19(14):2042-4. Epub 2005 Oct 17.

PMID:
16230333
[PubMed - indexed for MEDLINE]
Free Article
19.

Apigenin suppresses insulin-like growth factor I receptor signaling in human prostate cancer: an in vitro and in vivo study.

Shukla S, Gupta S.

Mol Carcinog. 2009 Mar;48(3):243-52. doi: 10.1002/mc.20475.

PMID:
18726972
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer.

Min Y, Adachi Y, Yamamoto H, Ito H, Itoh F, Lee CT, Nadaf S, Carbone DP, Imai K.

Cancer Res. 2003 Oct 1;63(19):6432-41.

PMID:
14559833
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk